Contact allergy to preservatives: ESSCA results with the baseline series, 2009–2012
Background Allergic contact dermatitis caused by biocides is common and causes significant patient morbidity. Objective To describe the current frequency and pattern of patch test reactivity to biocide allergens included in the baseline series of most European countries. Methods Data collected by th...
Gespeichert in:
Veröffentlicht in: | Journal of the European Academy of Dermatology and Venereology 2017-04, Vol.31 (4), p.664-671 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Allergic contact dermatitis caused by biocides is common and causes significant patient morbidity.
Objective
To describe the current frequency and pattern of patch test reactivity to biocide allergens included in the baseline series of most European countries.
Methods
Data collected by the European Surveillance System on Contact Allergies (ESSCA) network between 2009 and 2012 from 12 European countries were analysed.
Results
Methylisothiazolinone 0.2% aq. produced the highest prevalence of sensitization during the study period, with an overall prevalence of 4.5%. The mixture methylchloroisothiazolinone /methylisothiazolinone tested at 0.02% aq. followed closely, with 4.1% of positive reactions. Other preservatives with lower rates of sensitization, but still over 1%, include methyldibromo glutaronitrile (MDBGN) 0.5% pet. and iodopropynyl butylcarbamate (IPBC) 0.2% pet. Formaldehyde releasers and parabens yielded less than 1% positive reactions during the study period. Some regional differences in the prevalence of contact allergy to biocides among European countries were observed.
Conclusions
Contact allergy to biocides is common throughout Europe, and regional differences could be explained by differences in exposure or characteristics of the population tested. Timely regulatory action for isothiazolinones is required. Although MDBGN is banned from cosmetics products since 2005, sensitization prevalence has not appeared to plateau. IPBC is an emerging allergen with an increasing prevalence over the last few years, and its inclusion in the European baseline series may be appropriate. |
---|---|
ISSN: | 0926-9959 1468-3083 |
DOI: | 10.1111/jdv.14063 |